相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- The DELISH randomized clinical trial found no significant difference in weight loss between an adapted Mediterranean-style diet and a commercial weight-loss program among 360 primary care patients with obesity. - Both groups achieved modest, sustained weight loss of roughly 4–5 kilograms over 24 months, with the Mediterranean-style group showing significantly greater improvements in diet quality. - The Mediterranean-style intervention shifted participants toward more unsaturated fats and fewer carbohydrates, a pattern the authors suggest could reduce obesity-related morbidity if maintained long term. - Researchers note the diet-quality-focused approach may offer a reasonable option for people who cannot afford or wish to avoid weight-loss medications or surgery.
- Nearly 40% of adult blacklegged ticks collected from residential yards in Biltmore Forest, North Carolina, tested positive for Borrelia burgdorferi, the bacterium that causes Lyme disease. - The infection rate is comparable to parts of the Northeast, mid-Atlantic, and upper Midwest where Lyme disease is long established, signaling a southward expansion of the tick vector. - Researchers also detected Borrelia miyamotoi and Anaplasma phagocytophilum, possibly the farthest south these pathogens have been identified in blacklegged tick populations. - A diagnostic gap persists because many regional clinicians were trained when Lyme disease was considered absent from North Carolina, delaying timely diagnosis and treatment.
- LINGO1 was identified as a selective cell-surface target enriched in Ewing sarcoma cells through a stepwise prioritization strategy across multiple proteomic datasets. - Opicinumab-MMAE ADCs suppressed Ewing sarcoma tumor growth in xenograft models without overt toxicity, while free MMAE caused rapid body weight loss requiring early study termination. - A single dose of opicinumab-MMAE achieved more sustained tumor control compared with irinotecan, with no detectable liver or brain toxicity. - The findings support further evaluation of LINGO1-targeted ADCs in immunocompetent models and patient cohorts, as well as exploration of LINGO1-directed cellular therapies.
- A prospective cohort of 5,318 mother-child pairs across 18 US sites found that urinary phthalate and alternative plasticizer biomarkers were associated with shorter gestational length and lower birth weight-for-gestational-age z scores. - Each interquartile-range increase in summed diisononyl phthalate metabolites corresponded to roughly 0.6 fewer days of gestation, while detection of phthalic acid was linked to about 1.1 fewer days. - Summed phthalates and alternative plasticizers were associated with a 0.06-point lower birth weight-for-gestational-age z score, with associations generally stronger among male newborns. - The observational design and single midpregnancy urine sample limit causal inference, and only a subset of associations remained after correction for multiple comparisons.
- Researchers at North Carolina State University and University of North Carolina at Chapel Hill developed a self-powered microneedle patch that collects dermal interstitial fluid for biomarker analysis without requiring blood draws or external power sources. - The patch successfully collected measurable biomarker samples in as little as 15 minutes and stored them for at least 24 hours in proof-of-concept testing using synthetic skin models. - The technology targets cortisol monitoring initially but could expand to track glucose, lactate, and inflammation markers, offering a more comfortable and cost-effective alternative to traditional blood testing. - Human testing has begun and the research team is developing companion devices to analyze the collected samples while seeking industry partnerships for commercialization.
- A new FDA randomized controlled trial found that 5% of healthy adults developed elevated liver enzymes after taking low-dose CBD (5 mg/kg body weight) for four weeks, with women appearing more vulnerable than men. - Seven participants withdrew from the 201-person study due to clinical signs of potential drug-induced liver injury, though liver enzymes returned to normal within one to two weeks after stopping CBD. - The findings raise important safety questions for the $1.9 billion CBD market, as many consumers may be unaware of potential liver risks and assume CBD products are entirely benign. - Researchers recommend that doctors ask about CBD use during routine medical screening when liver chemistry results are abnormal, as symptoms of liver injury may not be immediately apparent.
- Beacon Therapeutics has exercised its option to license Abeona's patented AAV204 capsid technology for developing gene therapies targeting prevalent and rare retinal diseases that cause blindness. - The AAV204 capsid demonstrates superior retinal targeting capabilities, achieving high macular and optic nerve transduction levels in preclinical studies with mice and non-human primates. - Under the worldwide non-exclusive licensing agreement, Abeona will receive upfront payments plus development milestones and tiered royalties, while Beacon gains rights to use AAV204 for up to five ophthalmology disease targets.
- Continuity Biosciences has acquired Focal Medical, a North Carolina-based company developing site-specific chemotherapy using iontophoresis technology for pancreatic cancer treatment. - Focal Medical's lead product candidate uses an iontophoresis device to deliver gemcitabine directly to pancreatic tumors, which has received FDA IND clearance with Phase 1b trials expected to begin later this year. - The acquisition includes Focal Medical's patent estate, technology platform, and a dedicated R&D facility in Cary, NC, positioning Continuity as a leader in device-targeted therapeutics for solid tumors. - The iontophoresis approach enhances local drug concentration while minimizing systemic toxicity, addressing key limitations of traditional gemcitabine administration in pancreatic cancer.
- New data from the Phase 3 ENHANCE trials demonstrates that ensifentrine, a dual phosphodiesterase 3 and 4 inhibitor, significantly improves lung function and reduces exacerbations in COPD patients. - Ensifentrine monotherapy showed meaningful improvements in patient-reported outcomes including dyspnea, COPD symptoms, and health-related quality of life compared to placebo in patients not on long-acting medications. - As the first nebulized non-steroidal therapy with a novel dual mechanism of action, ensifentrine represents an important addition to the COPD treatment arsenal, offering benefits both as first-line and add-on therapy.
- A new experimental compound SHP1705 specifically targets circadian clock proteins hijacked by glioblastoma stem cells, impairing their ability to survive and grow in preclinical studies. - SHP1705 has successfully completed a Phase 1 clinical trial with 54 healthy participants, demonstrating safety and tolerability with only minor side effects reported. - The compound functions as a CRY activator, enhancing CRY2 protein activity which is found at reduced levels in glioblastoma cells, and shows potential to enhance radiation therapy effectiveness.
